November 5, 2026

Listing Department **Code: *532321***
BSE LIMITED
P J Towers, Dalal Street,
Mumbai-400001

Listing Department **Code: *ZYDUSLIFE***
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, C/1, Block G,
Bandra Kurla Complex,
Bandra (E),
Mumbai-400051

Re.: **Newspaper publication**

Ref.: Disclosure under regulation 30 read with regulations 33 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")

Dear Sir / Madam,

Pursuant to the provisions of regulation 30 read with regulations 33 and 47 of the Listing Regulations, please find attached the newspaper cutting with regard to publication of unaudited financial results for the quarter / half year ended on September 30, 2026, in Financial Express on November 5, 2026.

Please find the same in order.

Thanking you,

Yours faithfully,
For, **Zydus Lifesciences Limited**

DHAVAL NARENDRA SONI
Digitally signed by DHAVAL NARENDRA SONI
Date: 2026.11.05 12:04:26 +05'30'

Dhaval N. Soni
Company Secretary and Compliance Officer
Membership No. FCS7063

Encl.: As above

zydus
Dedicated To Life

Zydus Lifesciences Limited

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481
Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com
CIN : L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2026

INR Million

Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	79,096	80,170	61,232	159,266	126,969	271,484
2	Net profit for the period before exceptional items and tax	12,604	13,873	17,284	26,477	36,834	72,997
3	Net profit for the period after exceptional items but before tax	12,617	13,691	16,942	26,308	36,492	67,831
4	Net profit for the period after tax and non-controlling interest	9,255	9,604	12,609	18,859	27,277	50,947
5	Total comprehensive income for the period after tax and non-controlling interest	9,235	9,322	9,865	18,557	24,582	43,253
6	Paid-up equity share capital (Face value Re. 1/-)	998	998	1,006	998	1,006	1,006
7	Other equity						270,688
8	Earnings per share (not annualised for the quarter and half year)						
a	Basic (Rs.)	9.28	9.56	12.53	18.84	27.11	50.63
b	Diluted (Rs.)	9.28	9.56	12.53	18.84	27.11	50.63

Note:

[1] The above is an extract of the detailed format of Quarterly/ Half Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The results, alongwith the Limited Review Reports are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com] and can also be accessed by scanning the following QR Code:

By Order of the Board,
For Zydus Lifesciences Limited,

Date: November 4, 2026
Place: Ahmedabad

Dr. Sharvil P. Patel
Managing Director
DIN: 00131995

Zydus Lifesciences Limited

Dedicated To Life

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481
Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com
CIN : L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2026

INR Million

Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	79,096	80,170	61,232	159,266	126,969	271,484
2	Net profit for the period before exceptional items and tax	12,604	13,873	17,284	26,477	36,834	72,997
3	Net profit for the period after exceptional items but before tax	12,617	13,691	16,942	26,308	36,492	67,831
4	Net profit for the period after tax and non-controlling interest	9,255	9,604	12,609	18,859	27,277	50,947
5	Total comprehensive income for the period after tax and non-controlling interest	9,235	9,322	9,865	18,557	24,582	43,253
6	Paid-up equity share capital (Face value Re. 1/-)	998	998	1,006	998	1,006	1,006
7	Other equity						270,688
8	Earnings per share (not annualised for the quarter and half year)						
a	Basic (Rs.)	9.28	9.56	12.53	18.84	27.11	50.63
b	Diluted (Rs.)	9.28	9.56	12.53	18.84	27.11	50.63

Note:

[1] The above is an extract of the detailed format of Quarterly/ Half Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The results, alongwith the Limited Review Reports are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com] and can also be accessed by scanning the following QR Code:

By Order of the Board,
For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel
Managing Director
DIN: 00131995

Date: November 4, 2026
Place: Ahmedabad